Andrea Pantoja1, Sandra V Kik2, Claudia M Denkinger3. 1. Independent consultant for FIND, Zürich, Switzerland. 2. McGill International TB Centre and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada. 3. FIND, Geneva, Switzerland.
Abstract
BACKGROUND: Four priority target product profiles for the development of diagnostic tests for tuberculosis were identified: 1) Rapid sputum-based (RSP), 2) non-sputum Biomarker-based (BMT), 3) triage test followed by confirmatory test (TT), and 4) drug-susceptibility testing (DST). METHODS: We assessed the cost of the new tests in suitable strategies and of the conventional diagnosis of tuberculosis as per World Health Organization guidelines, in 36 high tuberculosis and MDR burden countries. Costs were then compared to the available funding for tuberculosis at country level. RESULTS: Costs of diagnosing tuberculosis using RSP ranged US$93-187 million/year; if RSP unit cost is of US$2-4 it would be lower/similar cost than conventional strategy with sputum smear microscopy (US$ 119 million/year). Using BMT (with unit cost of US$2-4) would cost US$70-121 million/year and be lower/comparable cost than conventional diagnostics. Using TT with TPP characteristics (unit cost of US$1-2) followed by Xpert would reduce diagnostic costs up to US$36 million/year. Costs of using different novel DST strategies for the diagnosis of drug resistance would be higher compared with conventional diagnosis. CONCLUSIONS: Introducing a TT or a biomarker test with optimal characteristics would be affordable from a cost and affordability perspective at the current available funding for tuberculosis. Additional domestic or donor funding would be needed in most countries to achieve affordability for other new diagnostic tests.
BACKGROUND: Four priority target product profiles for the development of diagnostic tests for tuberculosis were identified: 1) Rapid sputum-based (RSP), 2) non-sputum Biomarker-based (BMT), 3) triage test followed by confirmatory test (TT), and 4) drug-susceptibility testing (DST). METHODS: We assessed the cost of the new tests in suitable strategies and of the conventional diagnosis of tuberculosis as per World Health Organization guidelines, in 36 high tuberculosis and MDR burden countries. Costs were then compared to the available funding for tuberculosis at country level. RESULTS: Costs of diagnosing tuberculosis using RSP ranged US$93-187 million/year; if RSP unit cost is of US$2-4 it would be lower/similar cost than conventional strategy with sputum smear microscopy (US$ 119 million/year). Using BMT (with unit cost of US$2-4) would cost US$70-121 million/year and be lower/comparable cost than conventional diagnostics. Using TT with TPP characteristics (unit cost of US$1-2) followed by Xpert would reduce diagnostic costs up to US$36 million/year. Costs of using different novel DST strategies for the diagnosis of drug resistance would be higher compared with conventional diagnosis. CONCLUSIONS: Introducing a TT or a biomarker test with optimal characteristics would be affordable from a cost and affordability perspective at the current available funding for tuberculosis. Additional domestic or donor funding would be needed in most countries to achieve affordability for other new diagnostic tests.
Authors: Alexander C Kukhtin; Thomas Sebastian; Julia Golova; Alex Perov; Christopher Knickerbocker; Yvonne Linger; Arial Bueno; Peter Qu; Michael Villanueva; Rebecca C Holmberg; Darrell P Chandler; Christopher G Cooney Journal: Lab Chip Date: 2019-03-27 Impact factor: 6.799
Authors: Mary A De Groote; David G Sterling; Thomas Hraha; Theresa M Russell; Louis S Green; Kirsten Wall; Stephan Kraemer; Rachel Ostroff; Nebojsa Janjic; Urs A Ochsner Journal: J Clin Microbiol Date: 2017-08-09 Impact factor: 5.948
Authors: Rachel M Anderson de Cuevas; Lovett Lawson; Najla Al-Sonboli; Nasher Al-Aghbari; Isabel Arbide; Jeevan B Sherchand; Emenyonu E Nnamdi; Abraham Aseffa; Mohammed A Yassin; Saddiq T Abdurrahman; Joshua Obasanya; Oladimeji Olanrewaju; Daniel Datiko; Sally J Theobald; Andrew Ramsay; S Bertel Squire; Luis E Cuevas Journal: Infect Dis Poverty Date: 2016-03-24 Impact factor: 4.520